Top Story

Enzalutamide improved health-related quality of life in prostate cancer

August 26, 2014

Enzalutamide was associated with significant improvements in disease-related symptoms and all aspects of health-related quality of life among men with metastatic castration-resistant prostate cancer, according to results of the phase 3, double blind AFFIRM trial.

The trial included 1,199 patients who progressed during treatment with docetaxel.

figure In the Journals

Cancer screenings common among those with shortest life expectancies

August 18, 2014
A substantial proportion of older Americans with limited life expectancies undergo routine cancer screening despite the unlikely benefit of the tests in this population…
In the Journals

Age-restricted PSA screening could reduce preventable deaths, overdiagnosis

August 18, 2014
Routine PSA screening for all men aged younger than 70 years could prevent more than one-half of the avoidable prostate cancer deaths that would occur if screening were…
figure In the Journals

Long-term aspirin use reduced risk for cancer, cardiovascular events

August 14, 2014
Average-risk adults must adhere to a daily prophylactic aspirin regimen for 5 years to derive its protective benefits against cancer, myocardial infarction and stroke…
CME CNE

Treatment Decision-Making through the Spectrum of MDS: Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

8/20/2014
MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
figure

Docetaxel plus ADT improved OS in metastatic prostate cancer

June 24, 2014
CHICAGO — Donald L. Trump, MD, FACP, president and CEO at Roswell Park Cancer Institute and HemOnc Today
More »
CME

Applying Imaging, Biomarkers, and Immunotherapy in the Management of NSCLC

This activity is supported by an educational grant from Genentech, Inc.

8/7/2014
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, but the numerous subtypes make this disease…
More »

Filter By:

figure In the Journals

Enzalutamide improved health-related quality of life in prostate cancer

August 26, 2014
Enzalutamide was associated with significant improvements in disease-related symptoms and all aspects of health-related quality of life among men…
figure In the Journals

Cancer screenings common among those with shortest life expectancies

August 18, 2014
A substantial proportion of older Americans with limited life expectancies undergo routine cancer screening despite the unlikely benefit of the tests…
In the Journals

Age-restricted PSA screening could reduce preventable deaths, overdiagnosis

August 18, 2014
Routine PSA screening for all men aged younger than 70 years could prevent more than one-half of the avoidable prostate cancer deaths that would…
figure In the Journals

Long-term aspirin use reduced risk for cancer, cardiovascular events

August 14, 2014
Average-risk adults must adhere to a daily prophylactic aspirin regimen for 5 years to derive its protective benefits against cancer, myocardial…
In the Journals Perspective

Comorbid conditions determined appropriate age for cancer screening cessation

August 11, 2014
Models that account for individuals’ comorbid conditions may help determine the age at which they should stop undergoing breast, prostate and…
figure In the Journals

PSA screening reduced prostate cancer death by 21%, yet risks remain

August 6, 2014
Routine PSA testing for prostate cancer was associated with a significant reduction in death, according to 13-year follow-up from a randomized study…
FDA News

FDA panel votes against ablation ultrasound treatment for prostate cancer

August 1, 2014
An FDA panel recently rejected a high-focus ultrasound device as a treatment for low-risk, localized prostate cancer.The ultrasound system…
Institution Notes

Rutgers director receives award

HemOnc Today, August 25, 2014
Robert S. DiPaola, MD, director of Rutgers Cancer Institute of New Jersey, will receive the Melvyn H. Motolinsky Research Foundation Distinguished…
In the Journals

Men with short life expectancies often undergo aggressive prostate cancer treatment

July 29, 2014
Men with low- or intermediate-risk prostate cancer who had life expectancies of fewer than 10 years frequently underwent aggressive treatment with…
figure Cover Stories Publication Exclusive

Liquid biopsies provide extensive information, but technology carries ‘potential for overuse’

HemOnc Today, July 25, 2014
Researchers have known for decades that tumors shed cells and DNA into the bloodstream.
More Headlines »